Search research articles
Contact Us
Filters
Showing results (111-120 of 134) with videos related to
Page
of 14
Sort By:
Human Mutation
|
August 23, 2020
Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss caused by a mutation in RRM2B
Lisa Roberts, Stephanie Julius, Shrinav Dawlat, et al.
The International Journal of Biological Markers
|
September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy
Rimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
BMJ Open
|
May 29, 2016
Non-specific mechanisms in orthodox and CAM management of low back pain (MOCAM): theoretical framework and protocol for a prospective cohort study
Katherine Bradbury, Miznah Al-Abbadey, Dawn Carnes, et al.
JAMA Ophthalmology
|
August 21, 2020
Association of Sex With Frequent and Mild ABCA4 Alleles in Stargardt Disease
Esmee H Runhart, Mubeen Khan, Stéphanie S Cornelis, et al.
Investigational New Drugs
|
May 3, 2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, et al.
Molecular Cancer Research : MCR
|
October 15, 2009
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways
Xuesong Liu, Edward K Han, Mark Anderson, et al.
BMJ Open
|
August 22, 2020
Supporting self-management of low back pain with an internet intervention in primary care: a protocol for a randomised controlled trial of clinical and cost-effectiveness (SupportBack 2)
Adam W A Geraghty, Lisa Roberts, Jonathan Hill, et al.
Cancer Research
|
May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Andrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Neuro-Oncology
|
January 1, 2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
David A Reardon, Andrew B Lassman, Martin van den Bent, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 134) with videos related to
Sort By:
Page
of 14
Human Mutation
|
August 23, 2020
Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss caused by a mutation in RRM2B
Lisa Roberts, Stephanie Julius, Shrinav Dawlat, et al.
The International Journal of Biological Markers
|
September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy
Rimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
BMJ Open
|
May 29, 2016
Non-specific mechanisms in orthodox and CAM management of low back pain (MOCAM): theoretical framework and protocol for a prospective cohort study
Katherine Bradbury, Miznah Al-Abbadey, Dawn Carnes, et al.
JAMA Ophthalmology
|
August 21, 2020
Association of Sex With Frequent and Mild ABCA4 Alleles in Stargardt Disease
Esmee H Runhart, Mubeen Khan, Stéphanie S Cornelis, et al.
Investigational New Drugs
|
May 3, 2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, et al.
Molecular Cancer Research : MCR
|
October 15, 2009
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways
Xuesong Liu, Edward K Han, Mark Anderson, et al.
BMJ Open
|
August 22, 2020
Supporting self-management of low back pain with an internet intervention in primary care: a protocol for a randomised controlled trial of clinical and cost-effectiveness (SupportBack 2)
Adam W A Geraghty, Lisa Roberts, Jonathan Hill, et al.
Cancer Research
|
May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Andrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Neuro-Oncology
|
January 1, 2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
David A Reardon, Andrew B Lassman, Martin van den Bent, et al.
Page
of 14